Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study - Summary - MDSpire
Advertisement
Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study
To investigate the role of additional perilesional sampling in increasing detection rates of clinically significant prostate cancer (csPCa), defined as ISUP grade group 2 or higher, while minimizing the detection of clinically insignificant prostate cancer (ciPCa), defined as ISUP grade 1.
Key Findings:
The study aimed to determine if six additional perilesional biopsies could replace standard systematic cores without reducing csPCa detection rates, potentially improving patient outcomes.
Approximately 86% of csPCa are detected within a 10 mm radius of the PI-RADS lesion, highlighting the importance of targeted sampling.
Interpretation:
The findings suggest that perilesional biopsies may enhance detection rates of csPCa, but further high-quality studies, such as randomized controlled trials, are needed to confirm these results.
Limitations:
The study is non-randomized and conducted at a single center, which may limit generalizability and introduce biases.
The sample size and follow-up duration may not be sufficient to draw definitive conclusions about the efficacy of perilesional biopsies.
Conclusion:
Perilesional biopsies hold potential for improving prostate cancer detection strategies, but more robust evidence, particularly from randomized studies, is required.
by Gregor Duwe, Melanie Schmitteckert, Maximilian Haack, Peter Sparwasser, Robert Dotzauer, Anita Thomas, Igor Tsaur, Maximilian Peter Brandt, Martin Kurosch, Rene Mager, Axel Haferkamp, Katharina Boehm, Thomas Höfner
